Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Initial Dexamethasone Premedication Given Intravenously to Patients with Advanced Solid Tumors.

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Initial Dexamethasone Premedication Given Intravenously to Patients with Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hyaluronidase (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Halozyme Therapeutics

Most Recent Events

  • 26 Sep 2017 Results published in the British Journal of Cancer.
  • 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 05 Apr 2013 Data will be presented at the American Association for Cancer Research Annual Meeting 2013, according to a Sarah Cannon Research Institute media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top